ISRCTN51203558 https://doi.org/10.1186/ISRCTN51203558

Quality of life assessment and patient acceptability of intermittent versus continuous sex hormone suppression as treatment for locally advanced or metastatic prostatic cancer

Submission date
30/09/2005

Recruitment status
No longer recruiting

Registration date
30/09/2005

Overall study status
Completed

Last Edited
17/09/2012

Condition category
Cancer

[_] Prospectively registered
[_] Protocol
[_] Statistical analysis plan
[X] Results
[_] Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Mr Timothy Philp

Contact details
Consultant Urologist
WXUHT
London
United Kingdom
E11 1NR

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N0080056792

Study information

Scientific Title

Study objectives
This study will investigate patient acceptance, quality of life and survival/disease progression free interval in patients with locally advanced or metastatic prostate cancer in remission after six months treatment and disease control with androgen blockade.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Not Specified

Participant information sheet

Health condition(s) or problem(s) studied
Cancer: Prostate

Interventions
Intermittent vs continuous sex hormone suppression

Intervention Type
Other

Phase
Not Specified

Primary outcome measure
Patient acceptance, quality of life and survival/disease progression.

Secondary outcome measures

Not provided at time of registration

Overall study start date
31/12/1997

Completion date
31/12/2003

Eligibility

Key inclusion criteria
200 patients recruited from Urological Oncology Clinical who have had six months androgen blockade.

Participant type(s)
Patient

Age group
Not Specified

Sex
Male

Target number of participants
200

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
31/12/1997

Date of final enrolment
31/12/2003

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
Consultant Urologist
London
United Kingdom
E11 1NR

Sponsor information

Organisation
Department of Health

Sponsor details
Richmond House
79 Whitehall
London
United Kingdom
SW1A 2NL
+44 (0)20 7307 2622
dhmail@doh.gsi.org.uk

Sponsor type
Government

Website
http://www.dh.gov.uk/Home/fs/en

Funder(s)

Funder type
Charity

Funder Name
Orchid Cancer Appeal (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/10/2004		Yes	No